After the release of the second-quarter earnings report,Cantor FitzgeraldCombine biotech companiesAraviveThe rating was downgraded from “increase in holdings” to “neutral”, and its target price was changed from18The dollar was lowered to25cents. The bank said the company will be terminated unless more capital is raisedBatiraxceptofthe1b/ 2Phase clinical trial.
【BT机构股评】生物技术公司Aravive股票评级下调
[BT Agency Stock Review] Biotech company Aravive's stock rating downgraded
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.